Clinical Trial Update: A Study of ARQ 197 in Combination With Erlotinib [Phase 1]

View source ↗

Summary

Phase 1 study evaluating ARQ 197 in combination with erlotinib for advanced or recurrent non-small-cell lung cancer. The trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ARQ 197 (tivantinib)
• Tarceva (erlotinib)

Snippet

Sponsor: Kyowa Kirin Co., Ltd. | Conditions: Advanced/Recurrent Non-small-cell Lung Cancer | Phase 1 | Status: COMPLETED